EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

A Randomized Clinical Trial of 1-Dose vs Accelerated 2-Dose Schedule for Hepatitis A Virus (HAV) Revaccination Among People With Human Immunodeficiency Virus Who Were Nonresponders or Had Seroreversion After Primary HAV Vaccination

Guan-Jhou Chen iD, Hsin-Yun Sun iD, Kuan-Yin Lin, Szu-Min Hsieh iD, Yu-Chung Chuang, Wang-Da Liu, Yu-Shan Huang, Sung-Ching Pan, Un-In Wu, Aristine Cheng, Yi-Chia Huang, Cheng-Hsin Wu und 4 weitere

Clinical Infectious Diseases · 22.08.2023 · 77 (4) · 529-536

DOI: 10.1093/cid/ciad206 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 10.04.2023. Verfasst von Guan-Jhou Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Hepatitis A virus, Hepatitis A. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For people with human immunodeficiency virus (PWH) who have no serological responses to their primary hepatitis A virus (HAV) vaccination or have seroreversion after successful primary vaccination, the optimal revaccination strategy remains unclear.

Methods

In this open-label, randomized clinical trial, PWH who tested negative for anti-HAV antibodies after receiving a standard 2-dose series of primary HAV vaccination were enrolled and assigned in a 1:1 ratio to receive either 1 dose (the 1-dose group) or 2 doses of HAV vaccine administered 4 weeks apart (the 2-dose group). Serological response rates and anti-HAV antibody titers were compared at weeks 24 and 48.

Results

Of the 153 participants (77 in the 1-dose group and 76 in the 2-dose group), the overall serological response rates at week 48 after revaccination were similar between the 2 groups (2- vs 1-dose, 80.2% vs 71.4%, P = .20). However, anti-HAV antibody titers were consistently higher in the 2-dose group than in the 1-dose group. In subgroup analysis, PWH who were nonresponders to primary HAV vaccination were significantly more likely to mount a serological response after 2-dose HAV revaccination (68.4% vs 44.1%, P = .038). No severe adverse events were reported throughout the study.

Conclusions

Two-dose HAV revaccination administered 4 weeks apart yielded similar serological responses as 1-dose revaccination among PWH who were nonresponders or had seroreversion after primary HAV vaccination. The 2-dose revaccination schedule generated significantly higher anti-HAV antibody titers and was more likely to elicit serological responses at week 48 among PWH who were nonresponders to primary HAV vaccination. Clinical Trials Registration. NCT03855176.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis A virusHepatitis AHumansImmunization, SecondaryHIVHepatitis A AntibodiesVaccinationHepatitis A Vaccines

Stichwörter der Autor:innen

fecal–oral transmissionimmunizationmen who have sex with menoutbreakviral hepatitis

Substanzen

Hepatitis A AntibodiesHepatitis A Vaccines

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
  • Infection Control Room, Min-Sheng General Hospital, Taoyuan, Taiwan.
  • Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.
  • Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

ORCID-Profile: Guan-Jhou Chen, Hsin-Yun Sun, Szu-Min Hsieh, Chien-Ching Hung

Förderung

  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Chen, G. J., Sun, H. Y., Lin, K. Y., Hsieh, S. M., Chuang, Y. C., Liu, W. D., Huang, Y. S., Pan, S. C., Wu, U. I., Cheng, A., Huang, Y. C., Wu, C. H., Su, Y. C., Liu, W. C., Chang, S. Y., & Hung, C. C. (2023). A Randomized Clinical Trial of 1-Dose vs Accelerated 2-Dose Schedule for Hepatitis A Virus (HAV) Revaccination Among People With Human Immunodeficiency Virus Who Were Nonresponders or Had Seroreversion After Primary HAV Vaccination. Clinical Infectious Diseases, 77(4), 529-536. https://doi.org/10.1093/cid/ciad206

Vancouver

Chen GJ, Sun HY, Lin KY, Hsieh SM, Chuang YC, Liu WD, et al. A Randomized Clinical Trial of 1-Dose vs Accelerated 2-Dose Schedule for Hepatitis A Virus (HAV) Revaccination Among People With Human Immunodeficiency Virus Who Were Nonresponders or Had Seroreversion After Primary HAV Vaccination. Clinical Infectious Diseases. 2023;77(4):529-536. doi:10.1093/cid/ciad206

BibTeX
@article{Chen2023,
  author = {Chen, Guan-Jhou and Sun, Hsin-Yun and Lin, Kuan-Yin and Hsieh, Szu-Min and Chuang, Yu-Chung and Liu, Wang-Da and Huang, Yu-Shan and Pan, Sung-Ching and Wu, Un-In and Cheng, Aristine and Huang, Yi-Chia and Wu, Cheng-Hsin and Su, Yi-Ching and Liu, Wen-Chun and Chang, Sui-Yuan and Hung, Chien-Ching},
  title = {A Randomized Clinical Trial of 1-Dose vs Accelerated 2-Dose Schedule for Hepatitis A Virus (HAV) Revaccination Among People With Human Immunodeficiency Virus Who Were Nonresponders or Had Seroreversion After Primary HAV Vaccination},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {4},
  pages = {529--536},
  doi = {10.1093/cid/ciad206}
}
Kostenlos starten →